The most promising results were obtained from the FLINT trial, which demonstrated the capacity of the FXR agonist, OCA, to improve the histological features of MASH, including hepatic steatosis, hepatocyte ballooning, inflammation, and fibrosis [38]. This evidence concerns the gene NR1H4 and fatty liver disease.